We invest in ventures, because we believe that innovation and progress will improve the quality of life in the future.

We are fascinated by founders with visionary ideas and solid business skills – people who can take a good idea and build it into a great enterprise.

Our investment decisions are driven by a strong orientation towards the future. Following our guiding principle that “tomorrow happens today”, we finance start-ups in the present that will generate added value for society in the future.

For us, one of most important prerequisites for investment is to understand the technology and the product.

As a partner for start-ups, we offer strong financial backing, a long-term outlook and wide-ranging areas of expertise. We value mutual trust and, if necessary, are happy to get involved. As experienced business people ourselves, we are familiar with the challenges of running a successful company.

Investment focus

We invest in ventures in the fields of high-tech, digital and the life sciences.

As investors, we are essentially open-minded and interested in the challenging topics of the future.

If – after a thorough examination – we identify a specific potential for success, we invest in compelling start-ups that make sense. For us, the people behind a start-up, along with their vision and motivation, are the keys to success. Fundamentally speaking, the technology and the product must offer tangible benefits to potential customers.


We’re seeking

  • highly motivated founders and dynamic teams who are working to reach ambitious goals and change the future;
  • excellent technology and proucts with the potential to evolve, and strong patents.

We provide

  • initial financing in return for a minority stake from the seed stage onwards (from EUR 500,000 in the life sciences and high-tech industries, and from EUR 250,000 in the field of digital);
  • follow-up financing in the event of convincing results;
  • geographical focus on Germany and Switzerland

Portfolio excerpt


Numbrs develops and sells products for the execution of bank transactions, the purchasing of financial products and asset management. The namesake application is the market leader among bank-independent banking apps in Germany.


Based on immunohistochemical testing procedures, Lunaphore is developing a method to analyze tumor tissue more quickly and more precisely, thanks to microfluidic systems.


Using companion diagnostics, advanceCOR develops innovative medications for the personalized treatment of cardiovascular diseases. The company specializes in innovative biological medications in areas with strong medical demand, with development from the pre-clinical phase through to proof of concept in phase II studies on patients.

Show more projects


The Occident Ventures Team looks forward to receiving your e-mail at team@occident.ventures


Occident employees will be participating at the following events:

TOP 100 Swiss Startup Award 2020

09.09.2020, Zurich
Kathrin Chojnowska

Investforum Pitch Day

24.09.2020, Halle (Saale)
Cédric Barra

HTGF Family Day

05./06.10.2020, Bonn
Patrizia Schützenhöfer, Michael Pauer, Cédric Barra

Show more events